A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

NCT ID: NCT02281773

Last Updated: 2017-10-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 518 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-11-10
• Study Completion Date: 2016-06-13

Brief Summary

The objective of the study is to investigate the efficacy, safety and tolerability of four different doses of BI 409306 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment.

Conditions

Schizophrenia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

dose 1

Group Type: EXPERIMENTAL

BI 409306 10 mg QD

Intervention Type: DRUG

dose 2

Group Type: EXPERIMENTAL

BI 498306 25 mg QD

Intervention Type: DRUG

dose 3

Group Type: EXPERIMENTAL

BI 498306 50 mg QD

Intervention Type: DRUG

dose 4

Group Type: EXPERIMENTAL

BI 409306 100 mg QD

Intervention Type: DRUG

placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

BI 409306 100 mg QD

Intervention Type: DRUG

BI 498306 50 mg QD

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

BI 498306 25 mg QD

Intervention Type: DRUG

BI 409306 10 mg QD

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients with established diagnoses of schizophrenia (per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)) with the following clinical features:

a) Clinically stable and are in the residual (non-acute) phase of their illness for at least 8 weeks b) Current antipsychotic and concomitant psychotropic medications must meet the criteria below: b)-1 Maintained on current atypical (second generation) antipsychotic medications (in any approved dosage form) other than Clozapine and on current dose for at least 8 weeks prior to randomisation, and/or b)-2 Maintained on current typical (first generation) antipsychotic medications and on current dose for at least 6 months, optionally combined with anticholinergics if treated with a stable dose for at least 6 months prior to randomisation, and/or b)-3 Maintained on current concomitant psychotropic medications other than anticholinergics, antiepileptics and lithium, and on current dose for at least 8 weeks prior to randomisation. Antiepileptics and lithium are allowed if initiated at least 6 months prior to randomisation.

b)-4 Anticholinergics, antiepileptics and lithium have been washed out for at least 6 months prior to randomisation if the treatments that patients were using before entering the clinical trial are discontinued.

c) Have no more than a "moderate" severity rating on hallucinations and delusions (Positive and Negative Syndrome Scale (PANSS)-positive syndrome Hallucinatory Behavior item score < =4 and Delusions item score < = 4) d) Have no more than a "moderate" severity rating on positive formal thought disorder (PANSS-positive syndrome Conceptual Disorganization item score < = 4) e) Have a minimal level of extrapyramidal symptoms (Simpson-Angus Scale total score < 6) and depressive symptoms (PANSS-general psychopathology syndrome Depression item score < = 4)

2. Male or female patients age 18 to 55 years

3. Patients must exhibit reliability, physiologic capability, and an educational level sufficient to comply with all protocol procedures,in the investigator's opinion.

4. Signed and dated written informed consent by date of Visit 1 in accordance with GCP and the local legislation. If the patient needs a legal representative, then this legal representative must give written informed consent as well.

5. Patients must have an identified informant who will be consistent throughout the study. The informant must interact with the subject at least 2 times a week.

Note: Informant ratings are needed for SCoRS global ratings at Randomisation Visit (Visit 2) and (early) End of Treatment Visit. In person informant ratings on the study visits are preferred whenever possible. However, if the informant is not available for in person ratings, telephone interview is acceptable. The informant must be available for a telephone interview at Visit 2 and (e)EOT Visit.

Exclusion Criteria

1. Patient treated with more than two antipsychotic medications (including more than two dosage forms)

2. Patient's cognitive impairment severity compromises the validity of the cognitive outcome measures, in the clinical judgment of the investigator

3. Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior)

4. Any suicidal ideation of type 4 or 5 in the Columbia Suicidal Severity Rating Scale (C-SSRS) in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent)

5. In the judgment of the investigator, any clinically significant finding of the medical examination (including BP, PR and ECG) or laboratory value deviating from normal or any evidence of a clinically significant concomitant disease or any other clinical condition that would jeopardize a patient's safety while participating in the clinical trial

6. History or diagnosis of symptomatic and unstable/uncontrolled gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, hematological or hormonal disorders

7. For female patients:

Pre-menopausal women (last menstruation < =1 year prior to informed consent) who:

• are nursing or pregnant or
• are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the trial until 28 days after the last treatment administration, and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include tubal ligation, vasectomized partner, transdermal patch, intra uterine devices/systems (IUDs/IUSs), combined estrogen-progestin oral contraceptives as well as implantable or injectable hormonal contraceptives. Complete sexual abstinence (if acceptable by local health authorities) is allowed when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptom-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Double barrier methods are permissible (if acceptable by local health authorities, note that this is not an acceptable method in EU countries).

For male patients:

Men who are able to father a child, unwilling to be abstinent or use adequate contraception for the duration of study participation and for at least 28 days after treatment has ended.

8. Known history of HIV infection

9. Diseases of the central nervous system (including but not limited to any kind of seizures, stroke or any psychiatric disorders other than schizophrenia)

10. Any subject who on the Mini-international neuropsychiatric Interview (M.I.N.I.) has a categorical diagnosis of another current major psychiatric disorder.

11. History of malignancy within the last 5 years, except for basal cell carcinoma

12. Planned elective surgery requiring general anaesthesia, or hospitalisation for more than 1 day during the study period

13. Significant history of drug dependence or abuse (including alcohol, as defined in DSM-5-substance use disorder or in the opinion of the investigator) within the last two years prior to informed consent, or a positive urine drug screen for cocaine, opioid, PCP, amphetamine, heroin, or marijuana at screening

14. Patient needs to take long-acting hypnotics and anxiolytics (i.e. Diazepam)

15. Patients taking medications that are known to be strong or moderate CYP3A4 inhibitors

16. Participation in another trial with an investigational drug or procedure within 30 days or 6 half-lives (whichever is longer) or participation in another trial with any cognitive-enhancing therapy or procedure within 90 days prior to screening

17. Previous participation in any BI 409306 study

18. Not fluent in the language of the batteries/questionnaires which will be used in the country

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

K and S Professional Research Services, LLC

Little Rock, Arkansas, United States

Comprehensive Clinical Development, Inc.

Cerritos, California, United States

Collaborative Neuroscience Network

Garden Grove, California, United States

Pacific Institute of Medical Research

Los Angeles, California, United States

SRSD, Inc. dba Synergy San Diego

National City, California, United States

NRC Research Institute

Orange, California, United States

Artemis Institute for Clinical Research, LLC

San Diego, California, United States

Collaborative Neuroscience Network

Torrance, California, United States

Comprehensive Clinical Development

Washington D.C., District of Columbia, United States

Innovative Clinical Research

Lauderhill, Florida, United States

Florida Clinical Research Center

Maitland, Florida, United States

Behavioral Clinical Research, Inc.

North Miami, Florida, United States

Atlanta Center

Atlanta, Georgia, United States

Northwestern University

Chicago, Illinois, United States

Uptown Research Institute

Chicago, Illinois, United States

Lake Charles Clinical Trials LLC

Lake Charles, Louisiana, United States

Mid-America Clinical Research, LLC

St Louis, Missouri, United States

St. Louis Clinical Trials

St Louis, Missouri, United States

Neurobehavioral Research, Inc.

Cedarhurst, New York, United States

Finger Lakes Research

Rochester, New York, United States

University of Rochester Medical Center

Rochester, New York, United States

Richmond Behavioral Associates

Staten Island, New York, United States

Community Clinical Research, Inc.

Austin, Texas, United States

InSite Clinical Research

DeSoto, Texas, United States

Dr. Alexander McIntyre Inc.

Penticton, British Columbia, Canada

Depression, Mood Disorders and Schizophrenia Treatment Centr

Burlington, Ontario, Canada

Universitätsklinikum Köln (AöR)

Cologne, , Germany

LVR-Klinikum Düsseldorf

Düsseldorf, , Germany

Uniklinikum Heidelberg

Heidelberg, , Germany

Fujita Health University Hospital

Aichi, Toyoake, , Japan

Hokkaido University Hospital

Hokkaido, Sapporo, , Japan

Kobe University Hospital

Hyogo, Kobe, , Japan

Nara Medical University Hospital

Nara, Kashihara, , Japan

Kansai Med. Univ. Med. Ctr., Osaka, Neuropsychiatry

Osaka, Moriguchi-city, , Japan

Hizen Psychiatric Center, Saga, PSY

Saga, Kanzaki-gun, , Japan

Iwaki Clinic, Tokushima, Psychosomatic Medicine

Tokushima, Anan, , Japan

National Center Neurology and Psychiatry

Tokyo, Kodaira, , Japan

Showa University Karasuyama Hospital

Tokyo, Setagaya, , Japan

Showa University East Hospital

Tokyo, Shinagawa, , Japan

Chang-Hua Christian Hospital

Changhua, , Taiwan

Kai-Syuan Psychiatric Hospital

Kaohsiung City, , Taiwan

NCKUH

Tainan City, , Taiwan

Taipei City Hospital

Taipei, , Taiwan

Countries

Malaysia; United States; Canada; Germany; Japan; Taiwan

References

Dorner-Ciossek C, Kroker KS, Rosenbrock H. Role of PDE9 in Cognition. Adv Neurobiol. 2017;17:231-254. doi: 10.1007/978-3-319-58811-7_9.

Reference Type: DERIVED

PMID: 28956335 (View on PubMed)

Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophr Res. 2017 Dec;190:172-179. doi: 10.1016/j.schres.2017.03.040. Epub 2017 Apr 20.

Reference Type: DERIVED

PMID: 28433500 (View on PubMed)

Other Identifiers

2013-005015-28

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1289.6

Identifier Type: -

Identifier Source: org_study_id